Castle Biosciences Approved for Dual Listing on Nasdaq Texas

Castle Biosciences (Nasdaq: CSTL) has been approved for a dual listing of its common stock on Nasdaq Texas, a new Dallas-based exchange.

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL) has been approved for a dual listing of its common stock on Nasdaq Texas, a new Dallas-based exchange. The company will retain its primary listing on The Nasdaq Global Market, and trading on Nasdaq Texas is expected to begin today under the existing ticker CSTL.

According to Castle Biosciences, the dual listing aims to deepen its ties to Texas, enhance investor engagement and visibility, and support Texas’ development as a life sciences hub. The company stated that the move will not affect investors’ ability to trade its shares, nor its operations, reporting obligations, or capital structure.

Positive

• Dual listing approval on Nasdaq Texas with trading expected to begin Aug. 17, 2026
• Primary listing on The Nasdaq Global Market maintained under ticker CSTL
• No change to capital structure, reporting obligations, or business operations from dual listing
• Company expects enhanced investor visibility and engagement through additional exchange venue

Negative

• None.

Argus Aug 17 session 1 alert

+1.11% close to close 1.4x rel. volume Open Argus

Details

News Market Reaction – CSTL

$878.15M Market Cap

On Aug 17, the day this news came out, CSTL closed 1.11% above the previous close.

Data tracked by StockTitan Argus for the Aug 17 session.

Key Figures

Dual listing date: Aug. 17, 2026

Dual listing date

Aug. 17, 2026

Nasdaq Texas

Historical Context

5 past events · Latest: Jul 30

5 events

1. Jul 30

   Q2 earnings report

   24h Move

   +4.5%

   Revenue growth, raised guidance, and expected positive Adjusted EBITDA supported the report.

2. Jul 22

   Investor conference presentation

   24h Move

   +1.2%

   Management presentation at the Canaccord Genuity growth conference.

3. Jul 14

   State assay approval

   24h Move

   +3.9%

   New York approval expanded the company's portfolio of authorized tests.

4. Jul 09

   Earnings date announcement

   24h Move

   +3.9%

   The company scheduled its second-quarter results release and webcast.

5. Jun 25

   Clinical data release

   24h Move

   +6.1%

   The i31-SLNB risk prediction outperformed the MIA nomogram in prospective data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

dual listing, capital formation

2 terms

dual listing financial

"Castle will maintain its primary listing on The Nasdaq Global Market"

A dual listing is when a company makes the same shares available on two different stock exchanges, often in different countries, so investors can buy and sell the same ownership stake in more than one market—like a shop opening branches in two cities that sell the same product. It matters to investors because it can widen the pool of buyers, make shares easier to trade, expose the stock to different currencies and rules, and create price differences or arbitrage opportunities that affect returns and risk.

View in glossary

capital formation financial

"Texas' position as an ideal destination for public companies and capital formation"

Capital formation is the process by which businesses and economies gather money needed to grow and operate, for example through reinvesting profits, selling shares, or taking on loans. Think of it as filling a fuel tank that powers expansion, product development, or new projects. For investors, how effectively and cheaply capital is raised affects a company’s growth prospects, profit potential and the risk or dilution of existing holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary listing on The Nasdaq Global Market, and its common stock is expected to begin listing on Nasdaq Texas today under its existing ticker symbol, "CSTL."

"Castle was founded in Texas and remains deeply connected to the state's communities, talent and innovation ecosystem," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Our dual listing on Nasdaq Texas is an important reflection of those roots and our continued commitment to supporting Texas' growth as a hub for life sciences innovation while serving clinicians and patients through our portfolio of advanced testing solutions."

"Castle Biosciences is the kind of company Nasdaq Texas was built for: innovative, growth-oriented and forward-looking in every sense. We're proud to partner with a Texas-rooted leader that's making a meaningful impact on healthcare and helping prove that the future of innovation is being built right here in Texas," said Rachel Racz, president of Nasdaq Texas.

Nasdaq Texas is a newly established exchange designed to support public companies with strong ties to Texas and the broader region, while allowing issuers to maintain access to Nasdaq's global platform, technology and market infrastructure. Castle's dual listing is expected to support the Company's visibility among investors and align with Texas' continued growth as a center for business and innovation.

"Adding Nasdaq Texas provides Castle with an additional opportunity to engage with investors while maintaining our primary listing on The Nasdaq Global Market," said Frank Stokes, chief financial officer of Castle Biosciences. "We are pleased to support the launch of this new exchange and believe it underscores Texas' position as an ideal destination for public companies and capital formation, while supporting Castle's continued focus on expanding investor visibility and creating long-term shareholder value."

The dual listing will not affect investors' ability to buy or sell Castle's common stock, nor will it impact the Company's business operations, reporting obligations or capital structure.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X. 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning: Castle's expected commencement of trading on Nasdaq Texas; Castle's continued listing on The Nasdaq Global Market; Castle's expected continued access to Nasdaq's global platform, technology and market infrastructure; the expected benefits of the dual listing, including increased visibility, long-term shareholder value creation and investor access; our continued commitment to Texas' growth as a hub for life sciences innovation; and Castle's long-term strategy and ability to deliver innovative tests that guide patient care. The words "believe," "expect," "may," "will," "continue" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: trading on Nasdaq Texas may not commence on the expected timeline or at all; the dual listing may not result in the expected benefits, including increased visibility, long-term shareholder value creation or investor access; Castle may not realize the expected benefits of continued access to Nasdaq's global platform, technology or market infrastructure; changes to Castle's business strategy; and the risks set forth under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, and our subsequent Quarterly Reports on Form 10-Q, each as filed or to be filed with the SEC, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.

Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com

Media Contact:
Allison Marshall
amarshall@castlebiosciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/castle-biosciences-approved-for-dual-listing-on-nasdaq-texas-302852064.html

SOURCE Castle Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Castle Biosciences (CSTL) announce about its Nasdaq Texas listing on August 17, 2026?

Castle Biosciences announced approval for a dual listing of its common stock on Nasdaq Texas, effective August 17, 2026. According to Castle Biosciences, it will keep its primary listing on The Nasdaq Global Market while trading on Nasdaq Texas uses the existing ticker CSTL.

Will Castle Biosciences change its ticker symbol with the Nasdaq Texas dual listing?

Castle Biosciences will keep its existing ticker symbol, CSTL, on both exchanges. According to Castle Biosciences, its common stock is expected to begin listing on Nasdaq Texas under the CSTL symbol while remaining primarily listed on The Nasdaq Global Market.

How does the Nasdaq Texas dual listing affect Castle Biosciences shareholders and trading in CSTL stock?

The dual listing will not affect investors’ ability to buy or sell Castle Biosciences common stock. According to Castle Biosciences, the move does not change its operations, reporting obligations, or capital structure, and is expected to support additional investor engagement and visibility.

Why is Castle Biosciences (CSTL) pursuing a dual listing on Nasdaq Texas?

Castle Biosciences cites its Texas roots and desire to support Texas as a life sciences hub. According to Castle Biosciences, the Nasdaq Texas listing is expected to expand investor visibility and engagement while aligning with the state’s growth as a center for business and innovation.

Does Castle Biosciences’ Nasdaq Texas dual listing change its primary exchange or reporting obligations?

Castle Biosciences will maintain its primary listing on The Nasdaq Global Market despite the Nasdaq Texas dual listing. According to Castle Biosciences, the additional listing will not impact its reporting obligations, business operations, or capital structure for investors holding CSTL shares.

What is Nasdaq Texas and how does it relate to Castle Biosciences’ CSTL stock?

Nasdaq Texas is a newly established Dallas-based exchange designed for companies with strong ties to Texas. According to Castle Biosciences, dual listing CSTL on Nasdaq Texas allows it to leverage Nasdaq’s platform while strengthening connections to Texas-focused investors and the regional innovation ecosystem.